Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
07 Octubre 2024 - 3:01PM
Abivax Congratulates Victor Ambros
and Gary Ruvkun on Their Nobel Prize for the
Discovery of microRNA and its Role
in Post-Transcriptional Gene
Regulation
PARIS, France, October 7, 2024, 10:00
p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX)
(“Abivax” or the “Company”), a clinical-stage biotechnology company
focused on developing therapeutics that harness the body’s natural
regulatory mechanisms to stabilize the immune response in patients
with chronic inflammatory diseases, is thrilled to extend heartfelt
congratulations to Victor Ambros and Gary Ruvkun for being awarded
the Nobel Prize in Physiology or Medicine. Their groundbreaking
work in the field of microRNA has significantly advanced our
understanding of gene regulation and its implications for human
health.
Marc de Garidel, CEO of Abivax,
said, “The recognition of Ambros and Ruvkun underscores the
importance of microRNA research and its potential to transform
therapeutic approaches”. He went on to say “At Abivax, we are proud
to be at the forefront of innovative therapies that harness the
power of microRNAs. Our lead candidate, obefazimod, which is
currently being evaluated in a Phase 3 Trial clinical program for
Ulcerative Colitis and a Phase 2B Trial for Crohn’s Disease, acts
by enhancing expression of microRNA-124 (miR-124), which stabilizes
inflammatory pathways to reduce inflammation in patients with
chronic inflammatory conditions.”
Didier Scherrer, Chief Scientific
Officer at Abivax, stated, “We look forward to further
developing obefazimod and contributing to the evolving landscape of
treatments for ulcerative colitis and Crohn's disease with a new
mechanism of action, inspired by the pioneering work of luminaries
like Victor Ambros and Gary Ruvkun.”
About Obefazimod
Obefazimod, Abivax’s lead investigational drug
candidate, is an orally administered small molecule that was
demonstrated to potentially enhance the expression of a single
microRNA, miR-124. Phase 2 clinical trials in patients with
ulcerative colitis (UC) have generated positive data, resulting in
the initiation of a pivotal global Phase 3 clinical trial program
(ABTECT Program), with first patients enrolled in the United States
in October 2022. A Phase 2b clinical trial in Crohn’s disease is
ongoing, with the first patient enrolled in October 2024, and
exploration of potential combination therapy opportunities in UC is
ongoing.
About Abivax
Abivax is a clinical-stage biotechnology company
focused on developing therapeutics that harness the body’s natural
regulatory mechanisms to stabilize the immune response in patients
with chronic inflammatory diseases. Based in France and the United
States, Abivax’s lead drug candidate, obefazimod (ABX464), is in
Phase 3 clinical trials for the treatment of moderately to severely
active ulcerative colitis. More information on the Company is
available at www.abivax.com. Follow us on LinkedIn and on X,
formerly Twitter, @Abivax.
Contact:
Patrick MalloySVP, Investor Relations, Abivax
patrick.malloy@abivax.com +1 847 987 4878
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements, forecasts and estimates, including those relating to
the Company’s business and financial objectives. Words such as
“expect,” “plan,” “potential,” “will” and variations of such words
and similar expressions are intended to identify forward-looking
statements. These forward-looking statements include statements
concerning or implying the therapeutic potential of Abivax's drug
candidates and other statements that are not historical fact.
Although Abivax’s management believes that the expectations
reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and
statements are subject to various risks, contingencies and
uncertainties, many of which are difficult to predict and generally
beyond the control of Abivax, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. A description of these risks, contingencies and
uncertainties can be found in the documents filed by the Company
with the French Autorité des Marchés Financiers pursuant to its
legal obligations including its universal registration document
(Document d’Enregistrement Universel) and in our Annual Report on
Form 20-F filed with the U.S. Securities and Exchange Commission on
April 5, 2024 under the caption “Risk Factors.” These risks,
contingencies and uncertainties include, among other things, the
uncertainties inherent in research and development, future clinical
data and analysis, decisions by regulatory authorities, such as the
FDA or the EMA, regarding whether and when to approve any drug
candidate, as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates. Current results are not necessarily
indicative of future results. Special consideration should be given
to the potential hurdles of clinical and pharmaceutical development
including further assessment by the company and regulatory agencies
and IRBs/ethics committees following the assessment of preclinical,
pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data.
Furthermore, these forward-looking statements, forecasts and
estimates are only as of the date of this press release. Readers
are cautioned not to place undue reliance on these forward-looking
statements. Abivax disclaims any obligation to update these
forward-looking statements, forecasts or estimates to reflect any
subsequent changes that the Company becomes aware of, except as
required by law. Information about pharmaceutical products
(including products currently in development) that is included in
this press release is not intended to constitute an advertisement.
This press release is for information purposes only, and the
information contained herein does not constitute either an offer to
sell, or the solicitation of an offer to purchase or subscribe
securities of the Company in any jurisdiction. Similarly, it does
not give and should not be treated as giving investment advice. It
has no connection with the investment objectives, financial
situation or specific needs of any recipient. It should not be
regarded by recipients as a substitute for exercise of their own
judgment. All opinions expressed herein are subject to change
without notice. The distribution of this document may be restricted
by law in certain jurisdictions. Persons into whose possession this
document comes are required to inform themselves about and to
observe any such restrictions.
Abivax (EU:ABVX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Abivax (EU:ABVX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024